nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—Topoisomerase Inhibitors—Epirubicin—bone cancer	0.231	0.519	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Doxorubicin—bone cancer	0.214	0.481	CiPCiCtD
Mitoxantrone—breast cancer—bone cancer	0.112	0.389	CtDrD
Mitoxantrone—prostate cancer—bone cancer	0.104	0.361	CtDrD
Mitoxantrone—CYP3A4—bone cancer	0.0784	1	CbGaD
Mitoxantrone—sarcoma—bone cancer	0.0717	0.25	CtDrD
Mitoxantrone—TOP2A—Epirubicin—bone cancer	0.0314	0.228	CbGbCtD
Mitoxantrone—ABCC1—Epirubicin—bone cancer	0.0174	0.126	CbGbCtD
Mitoxantrone—TOP2A—Doxorubicin—bone cancer	0.0167	0.121	CbGbCtD
Mitoxantrone—CYP1B1—Doxorubicin—bone cancer	0.013	0.0944	CbGbCtD
Mitoxantrone—ABCG2—Carboplatin—bone cancer	0.0108	0.0783	CbGbCtD
Mitoxantrone—ABCC1—Doxorubicin—bone cancer	0.00924	0.067	CbGbCtD
Mitoxantrone—ABCG2—Cisplatin—bone cancer	0.00923	0.0669	CbGbCtD
Mitoxantrone—ABCC1—Methotrexate—bone cancer	0.00895	0.0649	CbGbCtD
Mitoxantrone—ABCG2—Doxorubicin—bone cancer	0.00618	0.0449	CbGbCtD
Mitoxantrone—ABCG2—Methotrexate—bone cancer	0.00599	0.0435	CbGbCtD
Mitoxantrone—ABCB1—Cisplatin—bone cancer	0.00333	0.0241	CbGbCtD
Mitoxantrone—ABCB1—Doxorubicin—bone cancer	0.00223	0.0162	CbGbCtD
Mitoxantrone—ABCB1—Methotrexate—bone cancer	0.00216	0.0157	CbGbCtD
Mitoxantrone—CYP3A4—Doxorubicin—bone cancer	0.00134	0.00969	CbGbCtD
Mitoxantrone—TOP2A—Gastric Cancer Network 1—C21orf33—bone cancer	0.00106	0.0609	CbGpPWpGaD
Mitoxantrone—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00078	0.0447	CbGpPWpGaD
Mitoxantrone—PIM1—Ectoderm Differentiation—BCOR—bone cancer	0.000659	0.0378	CbGpPWpGaD
Mitoxantrone—PIM1—IL3-mediated signaling events—IL3—bone cancer	0.000635	0.0364	CbGpPWpGaD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—T—bone cancer	0.000614	0.0352	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—BMI1—bone cancer	0.000607	0.0348	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.00057	0.0327	CbGpPWpGaD
Mitoxantrone—BTK—FAS (CD95) signaling pathway—RFC1—bone cancer	0.000529	0.0303	CbGpPWpGaD
Mitoxantrone—CYP1B1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000392	0.0225	CbGpPWpGaD
Mitoxantrone—CYP1B1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.000359	0.0206	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—EIF2S1—bone cancer	0.00034	0.0195	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000335	0.0192	CbGpPWpGaD
Mitoxantrone—ABCC1—Irinotecan Pathway—CYP3A4—bone cancer	0.00026	0.0149	CbGpPWpGaD
Mitoxantrone—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000256	0.0147	CbGpPWpGaD
Mitoxantrone—PIM1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.00023	0.0132	CbGpPWpGaD
Mitoxantrone—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.000229	0.0131	CbGpPWpGaD
Mitoxantrone—ABCC1—Sphingosine 1-phosphate (S1P) pathway—GNA11—bone cancer	0.000208	0.0119	CbGpPWpGaD
Mitoxantrone—CYP1B1—Estrogen metabolism—CYP3A4—bone cancer	0.000206	0.0118	CbGpPWpGaD
Mitoxantrone—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000194	0.0111	CbGpPWpGaD
Mitoxantrone—CYP1B1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000182	0.0104	CbGpPWpGaD
Mitoxantrone—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000182	0.0104	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000181	0.0104	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metapathway biotransformation—CYP4V2—bone cancer	0.000169	0.00968	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—CDK4—bone cancer	0.000167	0.00956	CbGpPWpGaD
Mitoxantrone—PIM1—C-MYB transcription factor network—KIT—bone cancer	0.000149	0.00856	CbGpPWpGaD
Mitoxantrone—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000148	0.00848	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000145	0.00834	CbGpPWpGaD
Mitoxantrone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000138	0.00794	CbGpPWpGaD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.000136	0.00781	CbGpPWpGaD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—ATF1—bone cancer	0.000129	0.00741	CbGpPWpGaD
Mitoxantrone—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.000124	0.00709	CbGpPWpGaD
Mitoxantrone—TOP2A—Idarubicin—Epirubicin—bone cancer	0.000123	0.173	CbGdCrCtD
Mitoxantrone—TOP2A—Doxorubicin—Epirubicin—bone cancer	0.000123	0.173	CbGdCrCtD
Mitoxantrone—TOP2A—Daunorubicin—Epirubicin—bone cancer	0.000123	0.173	CbGdCrCtD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—bone cancer	0.000119	0.00684	CbGpPWpGaD
Mitoxantrone—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000119	0.00682	CbGpPWpGaD
Mitoxantrone—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000119	0.00682	CbGpPWpGaD
Mitoxantrone—TOP2A—Daunorubicin—Doxorubicin—bone cancer	0.000114	0.16	CbGdCrCtD
Mitoxantrone—TOP2A—Idarubicin—Doxorubicin—bone cancer	0.000114	0.16	CbGdCrCtD
Mitoxantrone—TOP2A—Epirubicin—Doxorubicin—bone cancer	0.000114	0.16	CbGdCrCtD
Mitoxantrone—PIM1—C-MYB transcription factor network—PTGS2—bone cancer	0.000113	0.0065	CbGpPWpGaD
Mitoxantrone—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000112	0.00641	CbGpPWpGaD
Mitoxantrone—BTK—Activated TLR4 signalling—ATF1—bone cancer	0.000112	0.0064	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000111	0.00634	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.00011	0.00632	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—KIT—bone cancer	0.000107	0.00612	CbGpPWpGaD
Mitoxantrone—CYP1B1—Estrogen Receptor Pathway—JUN—bone cancer	0.000107	0.00612	CbGpPWpGaD
Mitoxantrone—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000106	0.00608	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—ATF1—bone cancer	0.000105	0.00602	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—MMP9—bone cancer	0.000105	0.00599	CbGpPWpGaD
Mitoxantrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000104	0.00598	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.000103	0.0059	CbGpPWpGaD
Mitoxantrone—BTK—IL-5 Signaling Pathway—JUN—bone cancer	9.98e-05	0.00572	CbGpPWpGaD
Mitoxantrone—CYP1B1—Tryptophan metabolism—CYP3A4—bone cancer	9.72e-05	0.00557	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.55e-05	0.00547	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—ATF1—bone cancer	9.35e-05	0.00536	CbGpPWpGaD
Mitoxantrone—ABCC1—S1P1 pathway—PTGS2—bone cancer	9.04e-05	0.00518	CbGpPWpGaD
Mitoxantrone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	8.09e-05	0.00464	CbGpPWpGaD
Mitoxantrone—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.86e-05	0.00451	CbGpPWpGaD
Mitoxantrone—CYP1B1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.76e-05	0.00445	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—DHFR—bone cancer	7.24e-05	0.00415	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.13e-05	0.00409	CbGpPWpGaD
Mitoxantrone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	7.13e-05	0.00409	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—JUN—bone cancer	7.12e-05	0.00408	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—TP53—bone cancer	7.09e-05	0.00406	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—BRAF—bone cancer	6.75e-05	0.00387	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—JUN—bone cancer	6.61e-05	0.00379	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	6.6e-05	0.00378	CbGpPWpGaD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—bone cancer	6.56e-05	0.00376	CbGpPWpGaD
Mitoxantrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	6.42e-05	0.00368	CbGpPWpGaD
Mitoxantrone—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	6.39e-05	0.00367	CbGpPWpGaD
Mitoxantrone—CYP1B1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.37e-05	0.00365	CbGpPWpGaD
Mitoxantrone—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	6.35e-05	0.00364	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—EGFR—bone cancer	6.26e-05	0.00359	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—ZW10—bone cancer	6.24e-05	0.00358	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.15e-05	0.00353	CbGpPWpGaD
Mitoxantrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	6.09e-05	0.00349	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.61e-05	0.00322	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—ZW10—bone cancer	5.58e-05	0.0032	CbGpPWpGaD
Mitoxantrone—Anaphylactic shock—Cisplatin—bone cancer	5.41e-05	0.00163	CcSEcCtD
Mitoxantrone—Oedema—Cisplatin—bone cancer	5.41e-05	0.00163	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	5.41e-05	0.0031	CbGpPWpGaD
Mitoxantrone—Anaphylactoid reaction—Doxorubicin—bone cancer	5.4e-05	0.00163	CcSEcCtD
Mitoxantrone—Infection—Cisplatin—bone cancer	5.37e-05	0.00162	CcSEcCtD
Mitoxantrone—Cardiac failure—Doxorubicin—bone cancer	5.36e-05	0.00162	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Cisplatin—bone cancer	5.3e-05	0.0016	CcSEcCtD
Mitoxantrone—Blood creatinine increased—Epirubicin—bone cancer	5.3e-05	0.0016	CcSEcCtD
Mitoxantrone—Tachycardia—Cisplatin—bone cancer	5.28e-05	0.00159	CcSEcCtD
Mitoxantrone—Dehydration—Epirubicin—bone cancer	5.26e-05	0.00159	CcSEcCtD
Mitoxantrone—Skin disorder—Cisplatin—bone cancer	5.25e-05	0.00159	CcSEcCtD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—TP53—bone cancer	5.25e-05	0.00301	CbGpPWpGaD
Mitoxantrone—Hyponatraemia—Doxorubicin—bone cancer	5.25e-05	0.00158	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—RB1—bone cancer	5.24e-05	0.00301	CbGpPWpGaD
Mitoxantrone—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	5.23e-05	0.00158	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Cisplatin—bone cancer	5.23e-05	0.00158	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Epirubicin—bone cancer	5.16e-05	0.00156	CcSEcCtD
Mitoxantrone—Anorexia—Cisplatin—bone cancer	5.16e-05	0.00156	CcSEcCtD
Mitoxantrone—Hypokalaemia—Epirubicin—bone cancer	5.14e-05	0.00155	CcSEcCtD
Mitoxantrone—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	5.14e-05	0.00294	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	5.12e-05	0.00293	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.11e-05	0.00293	CbGpPWpGaD
Mitoxantrone—Aspartate aminotransferase increased—Epirubicin—bone cancer	5.09e-05	0.00154	CcSEcCtD
Mitoxantrone—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	5.07e-05	0.00291	CbGpPWpGaD
Mitoxantrone—Hypotension—Cisplatin—bone cancer	5.06e-05	0.00152	CcSEcCtD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—JUN—bone cancer	5.04e-05	0.00289	CbGpPWpGaD
Mitoxantrone—Alanine aminotransferase increased—Epirubicin—bone cancer	4.99e-05	0.0015	CcSEcCtD
Mitoxantrone—Pancytopenia—Methotrexate—bone cancer	4.96e-05	0.0015	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Cisplatin—bone cancer	4.93e-05	0.00149	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—GNA11—bone cancer	4.92e-05	0.00282	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—JUN—bone cancer	4.91e-05	0.00282	CbGpPWpGaD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	4.91e-05	0.00281	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—EZH2—bone cancer	4.9e-05	0.00281	CbGpPWpGaD
Mitoxantrone—Blood creatinine increased—Doxorubicin—bone cancer	4.9e-05	0.00148	CcSEcCtD
Mitoxantrone—Neutropenia—Methotrexate—bone cancer	4.88e-05	0.00147	CcSEcCtD
Mitoxantrone—Dehydration—Doxorubicin—bone cancer	4.86e-05	0.00147	CcSEcCtD
Mitoxantrone—Paraesthesia—Cisplatin—bone cancer	4.86e-05	0.00147	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Methotrexate—bone cancer	4.85e-05	0.00146	CcSEcCtD
Mitoxantrone—Dyspnoea—Cisplatin—bone cancer	4.82e-05	0.00145	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Methotrexate—bone cancer	4.81e-05	0.00145	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Doxorubicin—bone cancer	4.78e-05	0.00144	CcSEcCtD
Mitoxantrone—Hypokalaemia—Doxorubicin—bone cancer	4.76e-05	0.00144	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—TUBB4B—bone cancer	4.73e-05	0.00271	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—KIT—bone cancer	4.72e-05	0.0027	CbGpPWpGaD
Mitoxantrone—Aspartate aminotransferase increased—Doxorubicin—bone cancer	4.71e-05	0.00142	CcSEcCtD
Mitoxantrone—Decreased appetite—Cisplatin—bone cancer	4.7e-05	0.00142	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—RB1—bone cancer	4.7e-05	0.0027	CbGpPWpGaD
Mitoxantrone—Pneumonia—Methotrexate—bone cancer	4.68e-05	0.00141	CcSEcCtD
Mitoxantrone—Drowsiness—Methotrexate—bone cancer	4.65e-05	0.0014	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.65e-05	0.00267	CbGpPWpGaD
Mitoxantrone—Pancytopenia—Epirubicin—bone cancer	4.64e-05	0.0014	CcSEcCtD
Mitoxantrone—Pain—Cisplatin—bone cancer	4.63e-05	0.0014	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Doxorubicin—bone cancer	4.61e-05	0.00139	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.59e-05	0.00263	CbGpPWpGaD
Mitoxantrone—Renal failure—Methotrexate—bone cancer	4.58e-05	0.00138	CcSEcCtD
Mitoxantrone—Neutropenia—Epirubicin—bone cancer	4.57e-05	0.00138	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Epirubicin—bone cancer	4.54e-05	0.00137	CcSEcCtD
Mitoxantrone—Stomatitis—Methotrexate—bone cancer	4.54e-05	0.00137	CcSEcCtD
Mitoxantrone—Conjunctivitis—Methotrexate—bone cancer	4.52e-05	0.00136	CcSEcCtD
Mitoxantrone—CYP1B1—Tryptophan metabolism—MDM2—bone cancer	4.47e-05	0.00256	CbGpPWpGaD
Mitoxantrone—Sweating—Methotrexate—bone cancer	4.46e-05	0.00135	CcSEcCtD
Mitoxantrone—Feeling abnormal—Cisplatin—bone cancer	4.46e-05	0.00134	CcSEcCtD
Mitoxantrone—Weight increased—Epirubicin—bone cancer	4.45e-05	0.00134	CcSEcCtD
Mitoxantrone—Haematuria—Methotrexate—bone cancer	4.44e-05	0.00134	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—KIT—bone cancer	4.44e-05	0.00254	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	4.44e-05	0.00254	CbGpPWpGaD
Mitoxantrone—Weight decreased—Epirubicin—bone cancer	4.42e-05	0.00133	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Epirubicin—bone cancer	4.41e-05	0.00133	CcSEcCtD
Mitoxantrone—Pneumonia—Epirubicin—bone cancer	4.38e-05	0.00132	CcSEcCtD
Mitoxantrone—Drowsiness—Epirubicin—bone cancer	4.36e-05	0.00131	CcSEcCtD
Mitoxantrone—BTK—Activated TLR4 signalling—JUN—bone cancer	4.35e-05	0.00249	CbGpPWpGaD
Mitoxantrone—Agranulocytosis—Methotrexate—bone cancer	4.34e-05	0.00131	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	4.31e-05	0.00247	CbGpPWpGaD
Mitoxantrone—Pancytopenia—Doxorubicin—bone cancer	4.29e-05	0.00129	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—RFC1—bone cancer	4.29e-05	0.00246	CbGpPWpGaD
Mitoxantrone—Renal failure—Epirubicin—bone cancer	4.28e-05	0.00129	CcSEcCtD
Mitoxantrone—Body temperature increased—Cisplatin—bone cancer	4.28e-05	0.00129	CcSEcCtD
Mitoxantrone—Stomatitis—Epirubicin—bone cancer	4.25e-05	0.00128	CcSEcCtD
Mitoxantrone—Jaundice—Epirubicin—bone cancer	4.25e-05	0.00128	CcSEcCtD
Mitoxantrone—Conjunctivitis—Epirubicin—bone cancer	4.23e-05	0.00128	CcSEcCtD
Mitoxantrone—Urinary tract infection—Epirubicin—bone cancer	4.23e-05	0.00128	CcSEcCtD
Mitoxantrone—Neutropenia—Doxorubicin—bone cancer	4.23e-05	0.00128	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—TUBB4B—bone cancer	4.23e-05	0.00242	CbGpPWpGaD
Mitoxantrone—Upper respiratory tract infection—Doxorubicin—bone cancer	4.2e-05	0.00127	CcSEcCtD
Mitoxantrone—Haemoglobin—Methotrexate—bone cancer	4.2e-05	0.00127	CcSEcCtD
Mitoxantrone—Haemorrhage—Methotrexate—bone cancer	4.18e-05	0.00126	CcSEcCtD
Mitoxantrone—Hepatitis—Methotrexate—bone cancer	4.18e-05	0.00126	CcSEcCtD
Mitoxantrone—Sweating—Epirubicin—bone cancer	4.18e-05	0.00126	CcSEcCtD
Mitoxantrone—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	4.17e-05	0.00239	CbGpPWpGaD
Mitoxantrone—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.16e-05	0.00239	CbGpPWpGaD
Mitoxantrone—Haematuria—Epirubicin—bone cancer	4.15e-05	0.00125	CcSEcCtD
Mitoxantrone—Pharyngitis—Methotrexate—bone cancer	4.15e-05	0.00125	CcSEcCtD
Mitoxantrone—Weight increased—Doxorubicin—bone cancer	4.11e-05	0.00124	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—KIT—bone cancer	4.11e-05	0.00235	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—JUN—bone cancer	4.09e-05	0.00234	CbGpPWpGaD
Mitoxantrone—Weight decreased—Doxorubicin—bone cancer	4.09e-05	0.00123	CcSEcCtD
Mitoxantrone—Sinusitis—Epirubicin—bone cancer	4.09e-05	0.00123	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Doxorubicin—bone cancer	4.08e-05	0.00123	CcSEcCtD
Mitoxantrone—Agranulocytosis—Epirubicin—bone cancer	4.07e-05	0.00123	CcSEcCtD
Mitoxantrone—Pneumonia—Doxorubicin—bone cancer	4.05e-05	0.00122	CcSEcCtD
Mitoxantrone—Drowsiness—Doxorubicin—bone cancer	4.03e-05	0.00122	CcSEcCtD
Mitoxantrone—CYP1B1—Arachidonic acid metabolism—PTGS2—bone cancer	4.03e-05	0.00231	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	4.01e-05	0.0023	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Cisplatin—bone cancer	3.99e-05	0.0012	CcSEcCtD
Mitoxantrone—Bradycardia—Epirubicin—bone cancer	3.98e-05	0.0012	CcSEcCtD
Mitoxantrone—Renal failure—Doxorubicin—bone cancer	3.96e-05	0.0012	CcSEcCtD
Mitoxantrone—Haemoglobin—Epirubicin—bone cancer	3.93e-05	0.00119	CcSEcCtD
Mitoxantrone—Stomatitis—Doxorubicin—bone cancer	3.93e-05	0.00119	CcSEcCtD
Mitoxantrone—Jaundice—Doxorubicin—bone cancer	3.93e-05	0.00119	CcSEcCtD
Mitoxantrone—Rhinitis—Epirubicin—bone cancer	3.92e-05	0.00118	CcSEcCtD
Mitoxantrone—Conjunctivitis—Doxorubicin—bone cancer	3.92e-05	0.00118	CcSEcCtD
Mitoxantrone—Urinary tract infection—Doxorubicin—bone cancer	3.92e-05	0.00118	CcSEcCtD
Mitoxantrone—Hepatitis—Epirubicin—bone cancer	3.91e-05	0.00118	CcSEcCtD
Mitoxantrone—Haemorrhage—Epirubicin—bone cancer	3.91e-05	0.00118	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.89e-05	0.00223	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	3.88e-05	0.00223	CbGpPWpGaD
Mitoxantrone—Asthenia—Cisplatin—bone cancer	3.88e-05	0.00117	CcSEcCtD
Mitoxantrone—Pharyngitis—Epirubicin—bone cancer	3.88e-05	0.00117	CcSEcCtD
Mitoxantrone—Sweating—Doxorubicin—bone cancer	3.86e-05	0.00117	CcSEcCtD
Mitoxantrone—Haematuria—Doxorubicin—bone cancer	3.84e-05	0.00116	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—RFC1—bone cancer	3.83e-05	0.0022	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDK4—bone cancer	3.81e-05	0.00218	CbGpPWpGaD
Mitoxantrone—Sinusitis—Doxorubicin—bone cancer	3.78e-05	0.00114	CcSEcCtD
Mitoxantrone—Agranulocytosis—Doxorubicin—bone cancer	3.76e-05	0.00113	CcSEcCtD
Mitoxantrone—Chills—Methotrexate—bone cancer	3.75e-05	0.00113	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—MDM2—bone cancer	3.71e-05	0.00213	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Cisplatin—bone cancer	3.7e-05	0.00112	CcSEcCtD
Mitoxantrone—Alopecia—Methotrexate—bone cancer	3.69e-05	0.00111	CcSEcCtD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	3.68e-05	0.00211	CbGpPWpGaD
Mitoxantrone—Bradycardia—Doxorubicin—bone cancer	3.68e-05	0.00111	CcSEcCtD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—JUN—bone cancer	3.64e-05	0.00209	CbGpPWpGaD
Mitoxantrone—Erythema—Methotrexate—bone cancer	3.64e-05	0.0011	CcSEcCtD
Mitoxantrone—Haemoglobin—Doxorubicin—bone cancer	3.64e-05	0.0011	CcSEcCtD
Mitoxantrone—Rhinitis—Doxorubicin—bone cancer	3.63e-05	0.00109	CcSEcCtD
Mitoxantrone—Haemorrhage—Doxorubicin—bone cancer	3.62e-05	0.00109	CcSEcCtD
Mitoxantrone—Hepatitis—Doxorubicin—bone cancer	3.62e-05	0.00109	CcSEcCtD
Mitoxantrone—Pharyngitis—Doxorubicin—bone cancer	3.59e-05	0.00108	CcSEcCtD
Mitoxantrone—Dysgeusia—Methotrexate—bone cancer	3.56e-05	0.00107	CcSEcCtD
Mitoxantrone—Back pain—Methotrexate—bone cancer	3.52e-05	0.00106	CcSEcCtD
Mitoxantrone—Chills—Epirubicin—bone cancer	3.51e-05	0.00106	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—MDM2—bone cancer	3.49e-05	0.002	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	3.49e-05	0.002	CbGpPWpGaD
Mitoxantrone—Arrhythmia—Epirubicin—bone cancer	3.49e-05	0.00105	CcSEcCtD
Mitoxantrone—Alopecia—Epirubicin—bone cancer	3.46e-05	0.00104	CcSEcCtD
Mitoxantrone—Vomiting—Cisplatin—bone cancer	3.44e-05	0.00104	CcSEcCtD
Mitoxantrone—Vision blurred—Methotrexate—bone cancer	3.43e-05	0.00103	CcSEcCtD
Mitoxantrone—Rash—Cisplatin—bone cancer	3.41e-05	0.00103	CcSEcCtD
Mitoxantrone—Dermatitis—Cisplatin—bone cancer	3.41e-05	0.00103	CcSEcCtD
Mitoxantrone—Erythema—Epirubicin—bone cancer	3.4e-05	0.00103	CcSEcCtD
Mitoxantrone—CYP1B1—Biological oxidations—CYP3A4—bone cancer	3.39e-05	0.00194	CbGpPWpGaD
Mitoxantrone—Ill-defined disorder—Methotrexate—bone cancer	3.38e-05	0.00102	CcSEcCtD
Mitoxantrone—Anaemia—Methotrexate—bone cancer	3.36e-05	0.00101	CcSEcCtD
Mitoxantrone—CYP1B1—Metapathway biotransformation—CYP3A4—bone cancer	3.34e-05	0.00191	CbGpPWpGaD
Mitoxantrone—Dysgeusia—Epirubicin—bone cancer	3.33e-05	0.00101	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—RB1—bone cancer	3.31e-05	0.0019	CbGpPWpGaD
Mitoxantrone—Back pain—Epirubicin—bone cancer	3.29e-05	0.000993	CcSEcCtD
Mitoxantrone—Malaise—Methotrexate—bone cancer	3.28e-05	0.000989	CcSEcCtD
Mitoxantrone—Leukopenia—Methotrexate—bone cancer	3.26e-05	0.000982	CcSEcCtD
Mitoxantrone—Chills—Doxorubicin—bone cancer	3.25e-05	0.000979	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—MDM2—bone cancer	3.23e-05	0.00185	CbGpPWpGaD
Mitoxantrone—Arrhythmia—Doxorubicin—bone cancer	3.23e-05	0.000975	CcSEcCtD
Mitoxantrone—Nausea—Cisplatin—bone cancer	3.21e-05	0.000969	CcSEcCtD
Mitoxantrone—Vision blurred—Epirubicin—bone cancer	3.21e-05	0.000968	CcSEcCtD
Mitoxantrone—Alopecia—Doxorubicin—bone cancer	3.2e-05	0.000964	CcSEcCtD
Mitoxantrone—Cough—Methotrexate—bone cancer	3.17e-05	0.000957	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Epirubicin—bone cancer	3.16e-05	0.000953	CcSEcCtD
Mitoxantrone—Convulsion—Methotrexate—bone cancer	3.15e-05	0.000951	CcSEcCtD
Mitoxantrone—Erythema—Doxorubicin—bone cancer	3.15e-05	0.00095	CcSEcCtD
Mitoxantrone—Anaemia—Epirubicin—bone cancer	3.15e-05	0.000949	CcSEcCtD
Mitoxantrone—Chest pain—Methotrexate—bone cancer	3.1e-05	0.000934	CcSEcCtD
Mitoxantrone—Arthralgia—Methotrexate—bone cancer	3.1e-05	0.000934	CcSEcCtD
Mitoxantrone—Myalgia—Methotrexate—bone cancer	3.1e-05	0.000934	CcSEcCtD
Mitoxantrone—Dysgeusia—Doxorubicin—bone cancer	3.08e-05	0.00093	CcSEcCtD
Mitoxantrone—Malaise—Epirubicin—bone cancer	3.07e-05	0.000926	CcSEcCtD
Mitoxantrone—Discomfort—Methotrexate—bone cancer	3.06e-05	0.000923	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	3.05e-05	0.00175	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	3.05e-05	0.00175	CbGpPWpGaD
Mitoxantrone—Leukopenia—Epirubicin—bone cancer	3.05e-05	0.000919	CcSEcCtD
Mitoxantrone—Back pain—Doxorubicin—bone cancer	3.05e-05	0.000919	CcSEcCtD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	3.04e-05	0.00174	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	3.04e-05	0.00174	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—ATF1—bone cancer	3.03e-05	0.00174	CbGpPWpGaD
Mitoxantrone—Confusional state—Methotrexate—bone cancer	2.99e-05	0.000903	CcSEcCtD
Mitoxantrone—Cough—Epirubicin—bone cancer	2.97e-05	0.000896	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Methotrexate—bone cancer	2.97e-05	0.000896	CcSEcCtD
Mitoxantrone—Vision blurred—Doxorubicin—bone cancer	2.97e-05	0.000895	CcSEcCtD
Mitoxantrone—Convulsion—Epirubicin—bone cancer	2.95e-05	0.00089	CcSEcCtD
Mitoxantrone—Infection—Methotrexate—bone cancer	2.95e-05	0.00089	CcSEcCtD
Mitoxantrone—Hypertension—Epirubicin—bone cancer	2.94e-05	0.000887	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Doxorubicin—bone cancer	2.92e-05	0.000882	CcSEcCtD
Mitoxantrone—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	2.92e-05	0.00167	CbGpPWpGaD
Mitoxantrone—Anaemia—Doxorubicin—bone cancer	2.91e-05	0.000878	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Methotrexate—bone cancer	2.91e-05	0.000877	CcSEcCtD
Mitoxantrone—Arthralgia—Epirubicin—bone cancer	2.9e-05	0.000874	CcSEcCtD
Mitoxantrone—Myalgia—Epirubicin—bone cancer	2.9e-05	0.000874	CcSEcCtD
Mitoxantrone—Chest pain—Epirubicin—bone cancer	2.9e-05	0.000874	CcSEcCtD
Mitoxantrone—CYP1B1—Biological oxidations—GSTP1—bone cancer	2.9e-05	0.00166	CbGpPWpGaD
Mitoxantrone—Anxiety—Epirubicin—bone cancer	2.89e-05	0.000871	CcSEcCtD
Mitoxantrone—Skin disorder—Methotrexate—bone cancer	2.88e-05	0.00087	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.88e-05	0.00165	CbGpPWpGaD
Mitoxantrone—Hyperhidrosis—Methotrexate—bone cancer	2.87e-05	0.000866	CcSEcCtD
Mitoxantrone—Discomfort—Epirubicin—bone cancer	2.86e-05	0.000864	CcSEcCtD
Mitoxantrone—CYP1B1—Metapathway biotransformation—GSTP1—bone cancer	2.86e-05	0.00164	CbGpPWpGaD
Mitoxantrone—Malaise—Doxorubicin—bone cancer	2.84e-05	0.000857	CcSEcCtD
Mitoxantrone—Anorexia—Methotrexate—bone cancer	2.83e-05	0.000854	CcSEcCtD
Mitoxantrone—Leukopenia—Doxorubicin—bone cancer	2.82e-05	0.00085	CcSEcCtD
Mitoxantrone—Confusional state—Epirubicin—bone cancer	2.8e-05	0.000845	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Epirubicin—bone cancer	2.78e-05	0.000838	CcSEcCtD
Mitoxantrone—Oedema—Epirubicin—bone cancer	2.78e-05	0.000838	CcSEcCtD
Mitoxantrone—Hypotension—Methotrexate—bone cancer	2.77e-05	0.000837	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—CDK4—bone cancer	2.77e-05	0.00159	CbGpPWpGaD
Mitoxantrone—Infection—Epirubicin—bone cancer	2.76e-05	0.000833	CcSEcCtD
Mitoxantrone—Cough—Doxorubicin—bone cancer	2.75e-05	0.000829	CcSEcCtD
Mitoxantrone—Shock—Epirubicin—bone cancer	2.73e-05	0.000825	CcSEcCtD
Mitoxantrone—Convulsion—Doxorubicin—bone cancer	2.73e-05	0.000823	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Epirubicin—bone cancer	2.72e-05	0.000821	CcSEcCtD
Mitoxantrone—Hypertension—Doxorubicin—bone cancer	2.72e-05	0.00082	CcSEcCtD
Mitoxantrone—Tachycardia—Epirubicin—bone cancer	2.71e-05	0.000818	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Methotrexate—bone cancer	2.7e-05	0.000816	CcSEcCtD
Mitoxantrone—Skin disorder—Epirubicin—bone cancer	2.7e-05	0.000814	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Epirubicin—bone cancer	2.69e-05	0.00081	CcSEcCtD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.68e-05	0.00154	CbGpPWpGaD
Mitoxantrone—Myalgia—Doxorubicin—bone cancer	2.68e-05	0.000809	CcSEcCtD
Mitoxantrone—Arthralgia—Doxorubicin—bone cancer	2.68e-05	0.000809	CcSEcCtD
Mitoxantrone—Chest pain—Doxorubicin—bone cancer	2.68e-05	0.000809	CcSEcCtD
Mitoxantrone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	2.68e-05	0.00153	CbGpPWpGaD
Mitoxantrone—Anxiety—Doxorubicin—bone cancer	2.67e-05	0.000806	CcSEcCtD
Mitoxantrone—Paraesthesia—Methotrexate—bone cancer	2.67e-05	0.000804	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—DHFR—bone cancer	2.66e-05	0.00152	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	2.65e-05	0.00152	CbGpPWpGaD
Mitoxantrone—Discomfort—Doxorubicin—bone cancer	2.65e-05	0.000799	CcSEcCtD
Mitoxantrone—Anorexia—Epirubicin—bone cancer	2.65e-05	0.000799	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	2.65e-05	0.00152	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Methotrexate—bone cancer	2.65e-05	0.000798	CcSEcCtD
Mitoxantrone—Somnolence—Methotrexate—bone cancer	2.64e-05	0.000796	CcSEcCtD
Mitoxantrone—Dyspepsia—Methotrexate—bone cancer	2.61e-05	0.000788	CcSEcCtD
Mitoxantrone—Hypotension—Epirubicin—bone cancer	2.6e-05	0.000783	CcSEcCtD
Mitoxantrone—Confusional state—Doxorubicin—bone cancer	2.59e-05	0.000782	CcSEcCtD
Mitoxantrone—Decreased appetite—Methotrexate—bone cancer	2.58e-05	0.000778	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Doxorubicin—bone cancer	2.57e-05	0.000775	CcSEcCtD
Mitoxantrone—Oedema—Doxorubicin—bone cancer	2.57e-05	0.000775	CcSEcCtD
Mitoxantrone—Fatigue—Methotrexate—bone cancer	2.56e-05	0.000772	CcSEcCtD
Mitoxantrone—Infection—Doxorubicin—bone cancer	2.55e-05	0.00077	CcSEcCtD
Mitoxantrone—Pain—Methotrexate—bone cancer	2.54e-05	0.000766	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—EGFR—bone cancer	2.54e-05	0.00145	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Epirubicin—bone cancer	2.53e-05	0.000764	CcSEcCtD
Mitoxantrone—Shock—Doxorubicin—bone cancer	2.53e-05	0.000763	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Doxorubicin—bone cancer	2.52e-05	0.000759	CcSEcCtD
Mitoxantrone—Tachycardia—Doxorubicin—bone cancer	2.51e-05	0.000757	CcSEcCtD
Mitoxantrone—Skin disorder—Doxorubicin—bone cancer	2.5e-05	0.000753	CcSEcCtD
Mitoxantrone—Paraesthesia—Epirubicin—bone cancer	2.49e-05	0.000753	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Doxorubicin—bone cancer	2.49e-05	0.00075	CcSEcCtD
Mitoxantrone—Dyspnoea—Epirubicin—bone cancer	2.48e-05	0.000747	CcSEcCtD
Mitoxantrone—Somnolence—Epirubicin—bone cancer	2.47e-05	0.000745	CcSEcCtD
Mitoxantrone—Anorexia—Doxorubicin—bone cancer	2.45e-05	0.000739	CcSEcCtD
Mitoxantrone—Feeling abnormal—Methotrexate—bone cancer	2.45e-05	0.000738	CcSEcCtD
Mitoxantrone—Dyspepsia—Epirubicin—bone cancer	2.45e-05	0.000738	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Methotrexate—bone cancer	2.43e-05	0.000732	CcSEcCtD
Mitoxantrone—Decreased appetite—Epirubicin—bone cancer	2.42e-05	0.000729	CcSEcCtD
Mitoxantrone—Hypotension—Doxorubicin—bone cancer	2.4e-05	0.000725	CcSEcCtD
Mitoxantrone—Fatigue—Epirubicin—bone cancer	2.4e-05	0.000723	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—EGFR—bone cancer	2.39e-05	0.00137	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	2.39e-05	0.00137	CbGpPWpGaD
Mitoxantrone—Pain—Epirubicin—bone cancer	2.38e-05	0.000717	CcSEcCtD
Mitoxantrone—Constipation—Epirubicin—bone cancer	2.38e-05	0.000717	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—DHFR—bone cancer	2.38e-05	0.00136	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.36e-05	0.00135	CbGpPWpGaD
Mitoxantrone—Urticaria—Methotrexate—bone cancer	2.36e-05	0.000711	CcSEcCtD
Mitoxantrone—Abdominal pain—Methotrexate—bone cancer	2.35e-05	0.000708	CcSEcCtD
Mitoxantrone—Body temperature increased—Methotrexate—bone cancer	2.35e-05	0.000708	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Doxorubicin—bone cancer	2.34e-05	0.000706	CcSEcCtD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.32e-05	0.00133	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Doxorubicin—bone cancer	2.31e-05	0.000696	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—bone cancer	2.3e-05	0.00132	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Doxorubicin—bone cancer	2.29e-05	0.000691	CcSEcCtD
Mitoxantrone—Feeling abnormal—Epirubicin—bone cancer	2.29e-05	0.000691	CcSEcCtD
Mitoxantrone—Somnolence—Doxorubicin—bone cancer	2.29e-05	0.000689	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Epirubicin—bone cancer	2.27e-05	0.000685	CcSEcCtD
Mitoxantrone—Dyspepsia—Doxorubicin—bone cancer	2.26e-05	0.000683	CcSEcCtD
Mitoxantrone—Decreased appetite—Doxorubicin—bone cancer	2.23e-05	0.000674	CcSEcCtD
Mitoxantrone—Fatigue—Doxorubicin—bone cancer	2.22e-05	0.000669	CcSEcCtD
Mitoxantrone—CYP2E1—Biological oxidations—CYP3A4—bone cancer	2.21e-05	0.00127	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—EGFR—bone cancer	2.21e-05	0.00127	CbGpPWpGaD
Mitoxantrone—Urticaria—Epirubicin—bone cancer	2.21e-05	0.000666	CcSEcCtD
Mitoxantrone—Constipation—Doxorubicin—bone cancer	2.2e-05	0.000663	CcSEcCtD
Mitoxantrone—Pain—Doxorubicin—bone cancer	2.2e-05	0.000663	CcSEcCtD
Mitoxantrone—Abdominal pain—Epirubicin—bone cancer	2.2e-05	0.000662	CcSEcCtD
Mitoxantrone—Body temperature increased—Epirubicin—bone cancer	2.2e-05	0.000662	CcSEcCtD
Mitoxantrone—Hypersensitivity—Methotrexate—bone cancer	2.19e-05	0.00066	CcSEcCtD
Mitoxantrone—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	2.18e-05	0.00125	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	2.17e-05	0.00125	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.14e-05	0.00123	CbGpPWpGaD
Mitoxantrone—Asthenia—Methotrexate—bone cancer	2.13e-05	0.000643	CcSEcCtD
Mitoxantrone—Feeling abnormal—Doxorubicin—bone cancer	2.12e-05	0.000639	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Doxorubicin—bone cancer	2.1e-05	0.000634	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—NDUFA12—bone cancer	2.1e-05	0.0012	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.06e-05	0.00118	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Epirubicin—bone cancer	2.05e-05	0.000617	CcSEcCtD
Mitoxantrone—Urticaria—Doxorubicin—bone cancer	2.04e-05	0.000616	CcSEcCtD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.04e-05	0.00117	CbGpPWpGaD
Mitoxantrone—Body temperature increased—Doxorubicin—bone cancer	2.03e-05	0.000613	CcSEcCtD
Mitoxantrone—Abdominal pain—Doxorubicin—bone cancer	2.03e-05	0.000613	CcSEcCtD
Mitoxantrone—Diarrhoea—Methotrexate—bone cancer	2.03e-05	0.000613	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism—NDUFA12—bone cancer	2.03e-05	0.00116	CbGpPWpGaD
Mitoxantrone—Asthenia—Epirubicin—bone cancer	1.99e-05	0.000601	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—CHEK2—bone cancer	1.99e-05	0.00114	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Epirubicin—bone cancer	1.9e-05	0.000573	CcSEcCtD
Mitoxantrone—Hypersensitivity—Doxorubicin—bone cancer	1.89e-05	0.000571	CcSEcCtD
Mitoxantrone—CYP2E1—Biological oxidations—GSTP1—bone cancer	1.89e-05	0.00108	CbGpPWpGaD
Mitoxantrone—Vomiting—Methotrexate—bone cancer	1.89e-05	0.000569	CcSEcCtD
Mitoxantrone—Rash—Methotrexate—bone cancer	1.87e-05	0.000565	CcSEcCtD
Mitoxantrone—Dermatitis—Methotrexate—bone cancer	1.87e-05	0.000564	CcSEcCtD
Mitoxantrone—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	1.87e-05	0.00107	CbGpPWpGaD
Mitoxantrone—Headache—Methotrexate—bone cancer	1.86e-05	0.000561	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.86e-05	0.00107	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	1.85e-05	0.00106	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NDUFA12—bone cancer	1.85e-05	0.00106	CbGpPWpGaD
Mitoxantrone—Asthenia—Doxorubicin—bone cancer	1.84e-05	0.000556	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—JUN—bone cancer	1.78e-05	0.00102	CbGpPWpGaD
Mitoxantrone—Vomiting—Epirubicin—bone cancer	1.77e-05	0.000533	CcSEcCtD
Mitoxantrone—BTK—Immune System—ATF1—bone cancer	1.76e-05	0.00101	CbGpPWpGaD
Mitoxantrone—Nausea—Methotrexate—bone cancer	1.76e-05	0.000532	CcSEcCtD
Mitoxantrone—Diarrhoea—Doxorubicin—bone cancer	1.76e-05	0.000531	CcSEcCtD
Mitoxantrone—Rash—Epirubicin—bone cancer	1.75e-05	0.000528	CcSEcCtD
Mitoxantrone—Dermatitis—Epirubicin—bone cancer	1.75e-05	0.000528	CcSEcCtD
Mitoxantrone—Headache—Epirubicin—bone cancer	1.74e-05	0.000525	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—NT5C3A—bone cancer	1.74e-05	0.000997	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—KIT—bone cancer	1.72e-05	0.000988	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IL3—bone cancer	1.72e-05	0.000986	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—BRCA2—bone cancer	1.68e-05	0.000965	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	1.68e-05	0.000964	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—NT5C3A—bone cancer	1.68e-05	0.000964	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—KIT—bone cancer	1.66e-05	0.000949	CbGpPWpGaD
Mitoxantrone—Nausea—Epirubicin—bone cancer	1.65e-05	0.000498	CcSEcCtD
Mitoxantrone—Vomiting—Doxorubicin—bone cancer	1.63e-05	0.000493	CcSEcCtD
Mitoxantrone—Rash—Doxorubicin—bone cancer	1.62e-05	0.000489	CcSEcCtD
Mitoxantrone—Dermatitis—Doxorubicin—bone cancer	1.62e-05	0.000488	CcSEcCtD
Mitoxantrone—Headache—Doxorubicin—bone cancer	1.61e-05	0.000486	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	1.53e-05	0.000878	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NT5C3A—bone cancer	1.53e-05	0.000877	CbGpPWpGaD
Mitoxantrone—Nausea—Doxorubicin—bone cancer	1.53e-05	0.000461	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	1.51e-05	0.000866	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.46e-05	0.000837	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	1.43e-05	0.000821	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDK4—bone cancer	1.4e-05	0.0008	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—MDM2—bone cancer	1.36e-05	0.000778	CbGpPWpGaD
Mitoxantrone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	1.35e-05	0.000776	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NDUFA12—bone cancer	1.33e-05	0.00076	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—MDM2—bone cancer	1.3e-05	0.000747	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	1.28e-05	0.000734	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.28e-05	0.000732	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDK4—bone cancer	1.25e-05	0.000715	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.23e-05	0.000703	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—RB1—bone cancer	1.21e-05	0.000696	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—JUN—bone cancer	1.18e-05	0.000676	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—bone cancer	1.18e-05	0.000675	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.1e-05	0.000632	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NT5C3A—bone cancer	1.1e-05	0.00063	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—RB1—bone cancer	1.09e-05	0.000622	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—KIT—bone cancer	1e-05	0.000576	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NDUFA12—bone cancer	9.98e-06	0.000572	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	9.49e-06	0.000544	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EGFR—bone cancer	9.28e-06	0.000532	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MDM2—bone cancer	9.25e-06	0.00053	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—ENO2—bone cancer	9.09e-06	0.000521	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—EGFR—bone cancer	8.91e-06	0.000511	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—GSTP1—bone cancer	8.77e-06	0.000503	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	8.65e-06	0.000496	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—DHFR—bone cancer	8.44e-06	0.000484	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NT5C3A—bone cancer	8.27e-06	0.000474	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—MDM2—bone cancer	7.91e-06	0.000453	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ENO2—bone cancer	7.61e-06	0.000437	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ENO2—bone cancer	7.37e-06	0.000422	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—DHFR—bone cancer	7.06e-06	0.000405	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	7.04e-06	0.000403	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—JUN—bone cancer	6.87e-06	0.000394	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—DHFR—bone cancer	6.83e-06	0.000392	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.78e-06	0.000389	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ENO2—bone cancer	6.7e-06	0.000384	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GNA11—bone cancer	6.6e-06	0.000379	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GNA11—bone cancer	6.39e-06	0.000366	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—DHFR—bone cancer	6.22e-06	0.000356	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NDUFA12—bone cancer	6.15e-06	0.000353	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	6.12e-06	0.000351	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TGFBR2—bone cancer	6.11e-06	0.00035	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CYP3A4—bone cancer	5.99e-06	0.000343	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.96e-06	0.000341	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GNA11—bone cancer	5.81e-06	0.000333	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CYP3A4—bone cancer	5.79e-06	0.000332	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.76e-06	0.00033	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EGFR—bone cancer	5.4e-06	0.00031	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—bone cancer	5.31e-06	0.000304	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CYP3A4—bone cancer	5.27e-06	0.000302	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GSTP1—bone cancer	5.12e-06	0.000293	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NT5C3A—bone cancer	5.1e-06	0.000292	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GSTP1—bone cancer	4.95e-06	0.000284	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ENO2—bone cancer	4.81e-06	0.000276	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.81e-06	0.000276	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GSTP1—bone cancer	4.5e-06	0.000258	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—DHFR—bone cancer	4.46e-06	0.000256	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—KIT—bone cancer	4.17e-06	0.000239	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GNA11—bone cancer	4.17e-06	0.000239	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.04e-06	0.000232	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—BRAF—bone cancer	3.92e-06	0.000225	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CYP3A4—bone cancer	3.78e-06	0.000217	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—ENO2—bone cancer	3.62e-06	0.000208	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—DHFR—bone cancer	3.36e-06	0.000193	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MDM2—bone cancer	3.29e-06	0.000188	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GSTP1—bone cancer	3.23e-06	0.000185	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTGS2—bone cancer	3.17e-06	0.000182	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GNA11—bone cancer	3.14e-06	0.00018	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CYP3A4—bone cancer	2.85e-06	0.000163	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTGS2—bone cancer	2.65e-06	0.000152	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTGS2—bone cancer	2.57e-06	0.000147	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GSTP1—bone cancer	2.44e-06	0.00014	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTGS2—bone cancer	2.33e-06	0.000134	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EGFR—bone cancer	2.24e-06	0.000129	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ENO2—bone cancer	2.23e-06	0.000128	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—DHFR—bone cancer	2.07e-06	0.000119	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GNA11—bone cancer	1.94e-06	0.000111	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTGS2—bone cancer	1.68e-06	9.61e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GSTP1—bone cancer	1.5e-06	8.6e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTGS2—bone cancer	1.26e-06	7.23e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTGS2—bone cancer	7.77e-07	4.46e-05	CbGpPWpGaD
